Company: BFRG
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023560
Chunk: 27

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Item 1
Chunk 27
---
, ranging from early pre-clinical through late-stage clinical
development. Our ultimate objective is to utilize bfLEAP™ to enable the success of ongoing third-party clinical trials or rescue
late-stage failed drugs (i.e., Phase II or Phase III clinical trial failures) for in-house development and divestiture. We will also
consider collaborations for earlier stage drugs.

We
intend to continue to evolve and improve bfLEAP™, either in-house or with development partners like JHU-APL. We plan to leverage
our proprietary AI/ML platform developed over several years at one of the top innovation institutions in the world, which has already
been successfully applied in multiple sectors.

We
operate and have staffed our business using funds from our initial public offering and subsequent financings, have entered into partnerships
and relationships, completed our first commercial service contract with a leading rare disease non-profit organization for AI/ML analysis
of late-stage clinical data in 2023, and we are partway through our collaboration agreement for clinical trial optimization with a Phase
III oncology company focused on novel chemotherapeutic treatments for rare cancers. We have also acquired the rights to a series of preclinical
and early clinical drug assets from universities, as well as entered into a strategic collaboration with a world-renowned research institution
to create a HSV1 viral therapeutic platform to engineer immunotherapies for a variety of diseases. We have signed exclusive worldwide
license agreements with Johns Hopkins University (“JHU”) for a cancer drug that targets glioblastoma (brain cancer), pancreatic
cancer, and others. We have also signed an exclusive worldwide license from George Washington University for another cancer drug that
targets hepatocellular carcinoma (liver cancer) and other liver diseases. In addition, we signed three-year strategic data and commercialization
agreements with the Lieber Institute for Brain Development (“LIBD”) whom we believe has a repository of the largest collection
of postmortem brains in the world, including molecular, clinical, and other data. The objective of this collaboration with LIBD is for
the Company to analyze these rich data sets using its proprietary AI/ML tools and models and then go to market with the discoveries with
the ultimate goal of securing revenue generating strategic partnership deals with biopharmaceutical companies. We intend to secure the
rights to other proprietary data sets and repeat this strategy. Additionally, we intend to gain access to later-stage clinical assets
through partnerships or the acquisition of rights to failed therapeutic candidates